NASDAQ:CAPR
Capricor Therapeutics Stock News
$5.01
-0.0400 (-0.792%)
At Close: Apr 19, 2024
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
10:56am, Wednesday, 10'th Apr 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the posi
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
10:56am, Monday, 25'th Mar 2024
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Capricor Therapeutics to Present at Upcoming Investor Conferences
08:30am, Thursday, 21'st Mar 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventi
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
10:56am, Thursday, 07'th Mar 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the posi
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
08:30am, Thursday, 22'nd Feb 2024
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and preventio
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
08:30pm, Tuesday, 14'th Nov 2023
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pant
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
09:15am, Tuesday, 07'th Nov 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
11:22am, Wednesday, 25'th Oct 2023
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
11:18am, Tuesday, 24'th Oct 2023
The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
06:42pm, Monday, 07'th Aug 2023
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantgin
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
04:01pm, Wednesday, 02'nd Aug 2023
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the trea
Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Con
Capricor Therapeutics, Inc. (CAPR) Q1 2023 Earnings Call Transcript
05:55pm, Thursday, 11'th May 2023
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseyno
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15
09:00am, Wednesday, 08'th Mar 2023
-Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET- -Company to Host Conference Call, March 15, 2023, at 4:30 p.m. ET-
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
02:25pm, Thursday, 16'th Feb 2023 GlobeNewswire Inc.
-Expands Partnership with Nippon Shinyaku to Japan to Leverage Deep Experience in Drug Development for Rare Diseases and Commercial DMD Franchise-
